Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS: Patient management considerations

BACKGROUND: Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with relapsing-remitting multiple sclerosis (MS), is a disease-modifying therapy with potential immunomodulatory and neuroprotective effects. In clinical trials, DMF was associated with reduced white blood c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurol Clin Pract
Main Authors: Fox, Robert J., Chan, Andrew, Gold, Ralf, Phillips, J. Theodore, Selmaj, Krzysztof, Chang, Ih, Novas, Mark, Rana, Jitesh, Marantz, Jing L.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2016
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4909524/
https://ncbi.nlm.nih.gov/pubmed/27347439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0000000000000238
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados